(Total Views: 198)
Posted On: 04/23/2022 7:20:03 PM
Post# of 1418
Tollovir still the only 3CL protease inhibitor shown to work for critical ill in hospitals. It's interesting these other companies don't even try. Long way to the top for others. Better for Todos I guess. Puts a lot of distance between us and them. Oh ad monster valuations I hear.
New Data for Shionogi's COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance - April 23, 2022 11:15 AM
https://www.benzinga.com/pressreleases/22/04/...-clearance
Gerald Commissiong@G_Commish Apr 20
"Tollovir compassionate use going well, will update on numbers soon. Final analysis with p values soon also. We have our strategy now and will be pushing hard Europe/US/Israel. Top level people getting behind 3CL Pharma, just got monster hosp valuation , Long COVID valuation next"
That 3rd party, independent valuation is key to negotiations. Let's say it's $100M. That means to get $10M of funding you aren't giving up much. But what if the valuation is North of $1B? It's entirely possible with key milestones. The other crap-o drugs are valued much higher.
New Data for Shionogi's COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance - April 23, 2022 11:15 AM
https://www.benzinga.com/pressreleases/22/04/...-clearance
Gerald Commissiong@G_Commish Apr 20
"Tollovir compassionate use going well, will update on numbers soon. Final analysis with p values soon also. We have our strategy now and will be pushing hard Europe/US/Israel. Top level people getting behind 3CL Pharma, just got monster hosp valuation , Long COVID valuation next"
That 3rd party, independent valuation is key to negotiations. Let's say it's $100M. That means to get $10M of funding you aren't giving up much. But what if the valuation is North of $1B? It's entirely possible with key milestones. The other crap-o drugs are valued much higher.
(2)
(0)Scroll down for more posts ▼
